Study to Evaluate Real-world Effectiveness With Palbociclib Plus Endocrine Therapy as First-line/Second-line Treatment for HR+/HER2- Advanced Breast Cancer in Japan
← catalyst calendarSponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
—
Status
Completed
Study type
Observational
Enrollment
693actual
Sites
20
Country
Japan
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-04-20 | actual | When the study began enrolling |
| Primary completion | 2025-06-27 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-06-27 | actual | The whole study's end, after follow-up |
| First posted | 2022-06-01 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-09 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Breast Cancer
Interventions
- Drug: Palbociclib
- Drug: Endocrine therapy
Primary outcomes
what the primary-completion date above is the date OFReal-World Progression-Free Survival (rwPFS) of palbociclib plus ET as first line treatment for HR+/HER2- ABC
measured 15 December 2017 to 31 August 2023
rePFS of palbociclib plus ET as second line treatment for HR+/HER2- ABC
measured 15 December 2017 to 31 August 2023
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed